Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on January 11, 2005. The filing discloses the Board of Directors' approval of the compensation program for independent directors for the 2005 fiscal year.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on non-employee director compensation terms.
- Annual Retainer: $45,000 per independent director.
- Meeting Fees: $2,000 per Board, Committee, or Annual Meeting attended.
- Committee Chair Fees: $10,000 annual fee for Chairs of the Audit, Compensation and Management Development, and Directors and Corporate Governance Committees.
- Equity Awards: 2,000 deferred common share units annually; options to purchase 2,500 shares granted at the Annual Meeting.
- Deferred Compensation: 25% of the retainer must be deferred into a BMS Stock account until ownership guidelines are met.
Material Changes Versus Prior Period
The Board approved that the compensation paid to each independent director during 2005 would remain the same as the compensation paid during 2004. No material changes to the compensation structure were reported.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of corporate risks. It details the terms of the Directors' Charitable Contribution Program, where the company purchases life insurance policies providing a $1 million death benefit. Upon a director's death, half of the benefit is donated to charities designated by the director, and the other half to the Bristol Myers Squibb Foundation. Directors derive no financial benefit from this program.
Key Facts for Investor Verification
- Confirm that 2005 director compensation terms are identical to 2004 levels.
- Verify the vesting schedule for stock options (four equal installments over four years).
- Note the mandatory 25% deferral of the annual retainer into company stock.
- Review the attached Exhibit 10(w) for the full summary of terms.